FindTrial
Sign In

Effects of branched-chain amino acid consumption in association with omega-3 in clinical-nutritional, cardiorespiratory, metabolic parameters and quality of life in cachectic patients

Impact of branched-chain amino acid supplementation on omega-3 association in clinical, nutritional, cardiorespiratory, metabolic parameters and quality of life in cachectic patients

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
REBEC
Registry ID
RBR-943djg
Enrollment
Unknown
Registered
2017-08-16
Start date
2017-07-01
Completion date
Unknown
Last updated
2025-10-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cachexia, cancer, heart failure

Interventions

Based on the mathematical formula of POCOCK (1983) used for paired samples, the sample will be composed of 22 cachectic patients, 11 individuals with heart failure collected at the Cardiology Outpatie
B) Supplementary Group with Omega 3 - supplementation of 6g / day of Omega 3 (EPA), six capsules (1000mg) per day, two before breakfast, two before lunch and two before dinner, for 28 days (4 weeks )
C) Supplementary group with combination of BCAA and Omega 3 - supplementation of 14.4 g / day of branched-chain amino acids and 6 g / day of omega-3 (EPA) for 28 days (4 weeks), with equal presentatio
Dietary supplement
SP6.051.227
D10.212.302.380.410
D12.125.070

Sponsors

Universidade Federal do Maranhão - UFMA
Lead Sponsor
Conselho Nacional de Desenvolvimento Científico e Tecnológico - CNPq
Collaborator
Fundação de Amparo à Pesquisa e ao Desenvolvimento Científico e Tecnológico do Maranhão - FAPEMA
Collaborator

Eligibility

Age
18 Years to 85 Years

Inclusion criteria

Inclusion criteria: Individuals over 18 years of age; pre-cachexia; cachexia; stability (absence of modifications in drug therapy in the last 6 weeks or hospitalizations in the last 3 months).

Exclusion criteria

Exclusion criteria: Individuals over 85 years of age; refractory cachexia (pre-terminal state, life expectancy <3 months, intense catabolism, lack of response to drug therapy); palliative care; use of branded step; water imbalance; allergy to nutritional composition of supplements; withdrawal of consent; adherence to intervention of less than 75%; refusal of proposed supplementation; worsening after intervention.

Design outcomes

Primary

MeasureTime frame
Effectiveness of branched chain amino acid supplementation in association with omega 3 in improving clinical, nutritional, cardiorespiratory, metabolic parameters and quality of life in cachectic patients.—

Secondary

MeasureTime frame
Recovery of anthropometric measures (weight, BMI, CB, PCT and AMB) and body composition (muscle, fat, cellular mass) after the intervention; Reduction of the frequency of sarcopenic patients after the intervention; Improvement in heart rate measurements, blood pressure control (SBP and DBP), as well as biochemical parameters (fasting glycemia, lipidogram, blood count, IL-1, IL-6, TNF-alpha, insulinemia, HOMA index, US, plasma adiponectin, albumin, pro-n-terminal natriuretic peptide) after the intervention; Improvement of functional capacity (IPAQ and TC6 classification) after the intervention; Improvement of muscle strength (dynamometry) after the intervention; Improved quality of life (Minnesota Living with Heart Failure Questionnaire and EORTC Quality of Life Questionnarie) after the intervention; Associate the intervention led to the reduction of the number of readmissions in less than 30 days and death of those evaluated.—

Countries

Brazil

Contacts

Public ContactAdriana;Alexsandro Teixeira;Santos

Universidade Federal do Maranhão - UFMA;Universidade Federal do Maranhão - UFMA

adrianaf.teixeira@hotmail.com;fs_alexsandro@yahoo.com.br+55 (98) 98892 3765;+55 (98) 98477 6125

Outcome results

None listed

Source: REBEC (via WHO ICTRP)